The content on this site is intended for healthcare professionals only
Dr Andrew Epstein and Prof Richard Schilsky comment on data, during a press conference at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, from a phase III randomised trial in which patients with surgically resected pancreatic cancer were treated with mFOLFIRINOX.
For more on these results, watch Dr Conroy present in the press conference here, watch Dr Conroys interview with ecancer here or read the news coverage here.
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 11th - 17th, 2023
Latest in immunological technologies that can treat, control, and prevent cancer
OncoAlert Round Up for August 4th - 10th, 2023
